At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- KarXT (drug), KarX-EC (drug)
- How long the study runs
- Study runs about 43 months (dates as stated)
- About the drug or intervention
- KarXT — drug: Specified dose on specified days · KarX-EC — drug: Specified dose on specified days
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 55 Years to 90 Years
- Who
- All
- Number of participants
- 650
- Started
- 2025-12-02
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for alzheimer disease
- • Phase3 - 650 participants
- • The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024
Who can take part?
- • Ages 55 Years to 90 Years
- • Diagnosed with alzheimer disease
Where?
- • Preston - Local Institution - 2505
- • Chertsey - Surrey and Borders Partnership NHS Foundation Trust
- • Cambridge - Local Institution - 2502
- • London - Local Institution - 2501
- • +6 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 55 Years - 90 Years
- Who can join: All genders
Treatment history
Treatments you must have had:
- ✓ completed study CN012-0023 or CN012-0024 per protocol
- ✓ an identified caregiver who has sufficient contact (approximately 8 hours over a week)
What the study is looking for
- ✓Participants must have completed study CN012-0023 or CN012-0024 per protocol.
- ✓Participants must have an identified caregiver who has sufficient contact (approximately 8 hours over a week).
Who cannot take part
- ✗Other protocol-defined Inclusion/Exclusion criteria apply.
See the full criteria
Where Is This Study? (10 UK sites)
Local Institution - 2505
Preston PR2 9HT, United Kingdom
Surrey and Borders Partnership NHS Foundation Trust
Chertsey KT16 9AU, United Kingdom
Local Institution - 2502
Cambridge CB21 5EF, United Kingdom
Local Institution - 2501
London SE5 8AZ, United Kingdom
Local Institution - 2500
London W12 0NN, United Kingdom
NeuroClin Glasgow
Motherwell ML1 4UF, United Kingdom
Cornwall Partnership NHS Foundation Trust
Redruth TR15 3QE, United Kingdom
Local Institution - 2504
Sheffield S5 7JT, United Kingdom
Local Institution - 2509
Stafford ST16 3SR, United Kingdom
Local Institution - 2503
Wolverhampton WV4 5HN, United Kingdom
How to Get in Touch
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com, www.BMSStudyConnect.com
Sponsor contactCONTACT
First line of the email MUST contain NCT # and Site #.
Sponsor contactCONTACT